Review of clinical practice guidelines for the management of LDL-related risk

Journal of the American College of Cardiology

Volumn 64, Issue 2, 2014, Pages 196-206

  Morris, Pamela B ^a   Ballantyne, Christie M ^b   Birtcher, Kim K ^c   Dunn, Steven P ^d   Urbina, Elaine M ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease prevention; cardiovascular risk assessment; clinical practice guidelines; gaps in care; LDL cholesterol; lipid management; special populations

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CANADIAN; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDUCATION PROGRAM; ENDOCRINOLOGIST; ETHNIC GROUP; EUROPEAN; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; TREATMENT PLANNING;

CARDIOVASCULAR DISEASE PREVENTION; CARDIOVASCULAR RISK ASSESSMENT; CLINICAL PRACTICE GUIDELINES; GAPS IN CARE; LDL CHOLESTEROL; LIPID MANAGEMENT; SPECIAL POPULATIONS;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DISEASE MANAGEMENT; HUMANS; MORBIDITY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84903940186     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.05.015     Document Type: Review

References (67)

1. J.A. Berliner, M. Navab, and A.M. Fogelman et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics Circulation 91 1995 2488 2496
2. Cholesterol Treatment Trialists' Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
3. H. Buchwald, C.T. Campos, and R.L. Varco et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH Arch Intern Med 158 1998 1253 1261
4. R.H. Eckel, J.M. Jakicic, and J.D. Ard et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2960 2984
5. K.A. Somma, D.L. Bhatt, and G.C. Fonarow et al. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction Circ Cardiovasc Interv 6 2013 e69 e79
6. A. Sachdeva, C.P. Cannon, and P.C. Deedwania et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines Am Heart J 157 2009 111 117.e2
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
8. National Cholesterol Education Program Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report Circulation 106 2002 3149 3421
9. P.W.F. Wilson, R.B. D'Agostino, and D. Levy et al. Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
10. S.M. Grundy, J.I. Cleeman, and C.N. Merz et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
11. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
12. J. Shepherd, G.J. Blauw, and M.B. Murphy et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
14. P.S. Sever, B. Dahlof, and N.R. Poulter et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
15. C.P. Cannon, E. Braunwald, and C.H. McCabe et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
16. S.M. Grundy, H. Arai, and P. Barter et al. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia Atherosclerosis 232 2014 410 413
17. D.M. Lloyd-Jones, E.P. Leip, and M.G. Larson et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
18. M.J. Pencina, R.B. D'Agostino Sr., and M.G. Larson et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart study Circulation 119 2009 3078 3084
19. J. Hippisley-Cox, C. Coupland, and Y. Vinogradova et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 BMJ 336 2008 1475 1482
20. G.S. Collins, and D.G. Altman Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2 BMJ 344 2012 e4181
21. J.D. Berry, A. Dyer, and X. Cai et al. Lifetime risks of cardiovascular disease N Engl J Med 366 2012 321 329
22. Z. Reiner, A. Catapano, and G. De Backer et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
23. R.M. Conroy, K. Pyorala, and A.P. Fitzgerald et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
24. J. Perk, G. De Backer, and H. Gohlke et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
25. G. Montalescot, U. Sechtem, and S. Achenbach et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology Eur Heart J 34 2013 2943 3003
26. L. Ryden, P.J. Grant, and S.D. Anker et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on Diabetes, Pre-diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur Heart J 34 2013 3035 3087
27. T.J. Anderson, J. Gregoire, and R.A. Hegele et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
28. G.H. Guyatt, A.D. Oxman, and G.E. Vist et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
29. R.B. D'Agostino Sr., R.S. Vasan, and M.J. Pencina et al. General cardiovascular risk profile for use in primary care: the Framingham Heart study Circulation 117 2008 743 753
30. P.S. Jellinger, D.A. Smith, and A.E. Mehta et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis Endocr Pract 18 Suppl 1 2012 S1 78
31. J.I. Mechanick, P.M. Camacho, and R.H. Cobin et al. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines - 2010 update Endocr Pract 16 2010 270 283
32. P.M. Ridker, J.E. Buring, and N. Rifai et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
33. P.M. Ridker, N.P. Paynter, and N. Rifai et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men Circulation 118 2008 2243 2251
34. S.S. Gidding, S.R. Daniels, and R.E. Kavey Expert Panel on Cardiovascular Health and Risk Reduction in Youth. Developing the 2011 Integrated Pediatric Guidelines for Cardiovascular Risk Reduction Pediatrics 129 2012 e1311 e1319
35. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report Pediatrics 128 Suppl 5 2011 S213 S256
36. J.L. Fleg, D.E. Forman, and K. Berra et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association Circulation 128 2013 2422 2446
37. L. Mosca, E.J. Benjamin, and K. Berra et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association Circulation 123 2011 1243 1262
38. J.D. Brunzell, M. Davidson, and C.D. Furberg et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
39. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 Suppl 1 2014 S14 S80
40. A.C. Goldberg, P.N. Hopkins, and P.P. Toth et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 Suppl 3 2011 S1 S8
41. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group KDIGO clinical practice guideline for lipid management in chronic kidney disease Kidney Int Suppl 3 2013 259 305
42. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41 Suppl 3 2003 S1 92
43. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 49 Suppl 2 2007 S12 154
44. V. Tsimihodimos, E. Dounousi, and K.C. Siamopoulos Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment Am J Nephrol 28 2008 958 973
45. M. Tonelli, P. Muntner, A. Lloyd for the Alberta Kidney Disease Network Association between LDL-C and risk of myocardial infarction in CKD J Am Soc Neph 24 2013 979 986
46. B.C. Fellström, A.G. Jardine, R.E. Schmieder for the AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
47. C. Wanner, V. Krane, W. März for the German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
48. C. Baigent, M.J. Landray, C. Reith on behalf of the SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
49. C. Baigent, K. Burbury, and D. Wheeler Premature cardiovascular disease in chronic renal failure Lancet 356 2000 147 152
50. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
51. G.H. Gibbons, S.B. Shurin, and G.A. Mensah et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute Circulation 128 2013 1713 1715
52. D.C. Goff Jr., D.M. Lloyd-Jones, and G. Bennett et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2935 2959
53. The ARIC Investigators The atherosclerosis risk in communities (ARIC) study: design and objectives Am J Epidemiol 129 1989 687 702
54. L.P. Fried, N.O. Borhani, and P. Enright et al. The cardiovascular health study: design and rationale Ann Epidemiol 1 1991 263 276
55. G.D. Friedman, G.R. Cutter, and R.P. Donahue et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects J Clin Epidemiol 41 1988 1105 1116
56. T.R. Dawber, W.B. Kannel, and L.P. Lyell An approach to longitudinal studies in a community: the Framingham study Ann New York Acad Sci 107 1963 539 556
57. W.B. Kannel, M. Feinleib, and P.M. McNamara et al. An investigation of coronary heart disease in families. The Framingham offspring study Am J Epidemiol 110 1979 281 290
58. M.J. Pencina, A.M. Navar-Boggan, and R.B. D'Agostino et al. Application of new cholesterol guidelines to a population-based sample N Engl J Med 370 2014 1422 1431
59. M. Kavousi, M.J.G. Leening, and D. Nanchen et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort JAMA 311 2014 1416 1423
60. P.M. Ridker, and N.R. Cook Statins: the new American guidelines for prevention of cardiovascular disease Lancet 382 2014 1762 1765
61. P. Muntner, L.D. Colantonio, and Cushman et al. Validation of the atherosclerotic cardiovascular pooled cohort risk equations JAMA 311 2014 1406 1415
62. D.J. Kumbhani, P.G. Steg, and C.P. Cannon et al. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis Am J Med 126 2013 693 700
63. C.A. Jackevicius, P. Li, and J.V. Tu Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction Circulation 117 2008 1028 1036
64. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention study Eur Heart J 18 1997 1718 1724
65. Medscape. Endocrinology group rejects new AHA/ACC CVD guidelines. Available at: http://www.medscape.com/viewarticle/817810. Accessed April 5, 2014.
66. The National Lipid Association. NLA statement on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Available at: https://www.lipid.org/nla/2013- accaha-guideline-treatment-blood-cholesterol-reduce-atherosclerotic- cardiovascular-risk. Accessed April 5, 2014.
67. The European Atherosclerosis Society. New guidelines in USA: how do they compare with the EAS/ESC Guidelines for the Management of Dyslipidaemia? Available at: http://www.eas-society.org/Newsletter-Archive.aspx?newsId=316. Accessed April 5, 2014.